An active lifestyle and improved quality of life

for the millions affected by chronic inflammatory diseases

An active lifestyle and improved quality of life

for the millions affected by chronic inflammatory diseases

RESEARCH & DEVELOPMENT

SOL-116 in clinical phase

Lipum’s drug candidate, SOL-116, has reached a significant milestone as we approach the final stage of the clinical phase 1 study.

FINANCIAL REPORTS

Q1 report

On May 28, Lipum presented its interim report for the frist quarter of 2024.

MEDIA /  PRESS RELEASES

Press

SOL-116 a drug candidate with groundbreaking potential

Lipum’s drug candidate SOL-116 is a humanized antibody expected to offer a unique mechanism of action for treatment of chronic inflammatory diseases such as rheumatoid arthritis (RA). Our goal is for SOL-116 to alleviate painful symptoms and improve the quality of life for the millions of patients suffering from chronic inflammatory diseases.

Lipum has completed the first part of the clinical phase 1 study, where healthy volunteers received a single dose of the drug candidate SOL-116. Interim results confirm an expected pharmacokinetic profile and a continued good safety profile, as well as SOL-116 interacting with its target protein BSSL (bile salt-stimulated lipase).

The story behind Lipum

Lipum AB (publ) was originally founded based on a discovery made by scientists at Umeå University. The history of the innovation goes back to the 1970s when Olle Hernell, Prof. of Pediatrics and his group was studying breast milk and the role of a lipase in the milk supporting efficient digestion of the milk fat in breastfed infants, an enzyme they gave the name Bile Salt-Stimulated Lipase (BSSL).

Redeye Life Science Day 2023

Einar Pontén and the new CEO, Ola Sandborgh, presents Lipum.
November 23, 2023